Global Dysmenorrhea Treatment Market

Dysmenorrhea Treatment Comprehensive Study by Application (Primary Dysmenorrhea, Secondary Dysmenorrhea), Treatment (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Hormonal Therapy), Drug Used (Ibuprofen, Ketoprofen, Naproxen), End-Use (Hospitals, Ambulatory Centres, Specialty Clinics) Players and Region - Global Market Outlook to 2028

Dysmenorrhea Treatment Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Dysmenorrhea, also called menstrual or period cramps, is cramping or throbbing pains within the lower abdomen. Most of the ladies experience dysmenorrhea just before and after completing their menstrual periods. Dysmenorrhea is of two types, namely primary and secondary dysmenorrhea. Dysmenorrhea are most likely caused by an excess of prostaglandins compounds that are released from the uterine lining as it prepares to be shed. Prostaglandin-induced uterine contractions cause dysmenorrhea and dysmenorrhea means pelvic pain caused by (secondary to) a disorder or disease. The occurrence of dysmenorrhea is highest in adolescent women, with ranging from approx. 20 to 90 percent. According to a study published within the International Journal of Gynecology & Obstetrics, dysmenorrhea affects over 80% of girls within the reproductive age, and it's the foremost common gynecological problem globally.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledBayer AG (Germany), GlaxoSmithKline plc (United Kingdom), Pfizer Inc. (United States), Teva Pharmaceuticals USA, Inc. (United States), Color Seven Co., Ltd. (South Korea), Beurer GmbH (Germany), Mylan N. V. (United States), Boehringer Ingelheim International GmbH (Germany), PMS4PMS, LLC (United States), Sanofi (France), Nobelpharma Co., Ltd. (Japan), ObsEva (Switzerland), Myovant Sciences Ltd. (United Kingdom), AbbVie Inc. (United States), Alvogen (United States), F. Hoffmann-La Roche Ltd (Switzerland), Sanofi (France), Lupin Pharmaceuticals, Inc. (India) and Sun Pharmaceutical Industries Ltd. (India)


This growth is primarily driven by Increasing Incidence and Prevalence of Dysmenorrhea and Increasing Usage of Medication for Dysmenorrhea.

Globally, a noticeable market trend is evident Rising Level of Awareness and Growing Concern about Dysmenorrhea among Women Major Players, such as Bayer AG (Germany), GlaxoSmithKline plc (United Kingdom), Pfizer Inc. (United States), Teva Pharmaceuticals USA, Inc. (United States), Color Seven Co., Ltd. (South Korea), Beurer GmbH (Germany), Mylan N. V. (United States), Boehringer Ingelheim International GmbH (Germany), PMS4PMS, LLC (United States), Sanofi (France), Nobelpharma Co., Ltd. (Japan), ObsEva (Switzerland), Myovant Sciences Ltd. (United Kingdom), AbbVie Inc. (United States), Alvogen (United States), F. Hoffmann-La Roche Ltd (Switzerland), Sanofi (France), Lupin Pharmaceuticals, Inc. (India) and Sun Pharmaceutical Industries Ltd. (India), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Key Developments in the Market:
In July 2020, Teva Pharmaceuticals USA, Inc., which Takeda holds as a joint business venture in the Japanese market, announced a new strategy for its local trading activities. This strategy has strengthened the company's presence in the Japanese market and drive sales growth.

Influencing Trend:
Rising Level of Awareness and Growing Concern about Dysmenorrhea among Women

Market Growth Drivers:
Increasing Incidence and Prevalence of Dysmenorrhea and Increasing Usage of Medication for Dysmenorrhea

Restraints:
Side Effects and Complications Associated with Long Term Treatment

Opportunities:
The Involvement of Companies in R&D for Innovative Medicines

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Dysmenorrhea Treatment Market
- Analysis about New Entrants in Dysmenorrhea Treatment Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Dysmenorrhea Treatment Study Sheds Light on
— The Dysmenorrhea Treatment Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Dysmenorrhea Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Dysmenorrhea Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Primary Dysmenorrhea
  • Secondary Dysmenorrhea
By Treatment
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Hormonal Therapy

By Drug Used
  • Ibuprofen
  • Ketoprofen
  • Naproxen

By End-Use
  • Hospitals
  • Ambulatory Centres
  • Specialty Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence and Prevalence of Dysmenorrhea
      • 3.2.2. Increasing Usage of Medication for Dysmenorrhea
    • 3.3. Market Trends
      • 3.3.1. Rising Level of Awareness and Growing Concern about Dysmenorrhea among Women
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dysmenorrhea Treatment, by Application, Treatment, Drug Used, End-Use and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Dysmenorrhea Treatment (Value)
      • 5.2.1. Global Dysmenorrhea Treatment by: Application (Value)
        • 5.2.1.1. Primary Dysmenorrhea
        • 5.2.1.2. Secondary Dysmenorrhea
      • 5.2.2. Global Dysmenorrhea Treatment by: Treatment (Value)
        • 5.2.2.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
        • 5.2.2.2. Hormonal Therapy
      • 5.2.3. Global Dysmenorrhea Treatment by: Drug Used (Value)
        • 5.2.3.1. Ibuprofen
        • 5.2.3.2. Ketoprofen
        • 5.2.3.3. Naproxen
      • 5.2.4. Global Dysmenorrhea Treatment by: End-Use (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Ambulatory Centres
        • 5.2.4.3. Specialty Clinics
      • 5.2.5. Global Dysmenorrhea Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Dysmenorrhea Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva Pharmaceuticals USA, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Color Seven Co., Ltd. (South Korea)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Beurer GmbH (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mylan N. V. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Boehringer Ingelheim International GmbH (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. PMS4PMS, LLC (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sanofi (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Nobelpharma Co., Ltd. (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. ObsEva (Switzerland)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Myovant Sciences Ltd. (United Kingdom)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. AbbVie Inc. (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Alvogen (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Sanofi (France)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
      • 6.4.18. Lupin Pharmaceuticals, Inc. (India)
        • 6.4.18.1. Business Overview
        • 6.4.18.2. Products/Services Offerings
        • 6.4.18.3. Financial Analysis
        • 6.4.18.4. SWOT Analysis
      • 6.4.19. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.19.1. Business Overview
        • 6.4.19.2. Products/Services Offerings
        • 6.4.19.3. Financial Analysis
        • 6.4.19.4. SWOT Analysis
  • 7. Global Dysmenorrhea Treatment Sale, by Application, Treatment, Drug Used, End-Use and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Dysmenorrhea Treatment (Value)
      • 7.2.1. Global Dysmenorrhea Treatment by: Application (Value)
        • 7.2.1.1. Primary Dysmenorrhea
        • 7.2.1.2. Secondary Dysmenorrhea
      • 7.2.2. Global Dysmenorrhea Treatment by: Treatment (Value)
        • 7.2.2.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
        • 7.2.2.2. Hormonal Therapy
      • 7.2.3. Global Dysmenorrhea Treatment by: Drug Used (Value)
        • 7.2.3.1. Ibuprofen
        • 7.2.3.2. Ketoprofen
        • 7.2.3.3. Naproxen
      • 7.2.4. Global Dysmenorrhea Treatment by: End-Use (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Ambulatory Centres
        • 7.2.4.3. Specialty Clinics
      • 7.2.5. Global Dysmenorrhea Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dysmenorrhea Treatment: by Application(USD Million)
  • Table 2. Dysmenorrhea Treatment Primary Dysmenorrhea , by Region USD Million (2017-2022)
  • Table 3. Dysmenorrhea Treatment Secondary Dysmenorrhea , by Region USD Million (2017-2022)
  • Table 4. Dysmenorrhea Treatment: by Treatment(USD Million)
  • Table 5. Dysmenorrhea Treatment Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) , by Region USD Million (2017-2022)
  • Table 6. Dysmenorrhea Treatment Hormonal Therapy , by Region USD Million (2017-2022)
  • Table 7. Dysmenorrhea Treatment: by Drug Used(USD Million)
  • Table 8. Dysmenorrhea Treatment Ibuprofen , by Region USD Million (2017-2022)
  • Table 9. Dysmenorrhea Treatment Ketoprofen , by Region USD Million (2017-2022)
  • Table 10. Dysmenorrhea Treatment Naproxen , by Region USD Million (2017-2022)
  • Table 11. Dysmenorrhea Treatment: by End-Use(USD Million)
  • Table 12. Dysmenorrhea Treatment Hospitals , by Region USD Million (2017-2022)
  • Table 13. Dysmenorrhea Treatment Ambulatory Centres , by Region USD Million (2017-2022)
  • Table 14. Dysmenorrhea Treatment Specialty Clinics , by Region USD Million (2017-2022)
  • Table 15. South America Dysmenorrhea Treatment, by Country USD Million (2017-2022)
  • Table 16. South America Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 17. South America Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 18. South America Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 19. South America Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 20. Brazil Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 21. Brazil Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 22. Brazil Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 23. Brazil Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 24. Argentina Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 25. Argentina Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 26. Argentina Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 27. Argentina Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 28. Rest of South America Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 29. Rest of South America Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 30. Rest of South America Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 31. Rest of South America Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 32. Asia Pacific Dysmenorrhea Treatment, by Country USD Million (2017-2022)
  • Table 33. Asia Pacific Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 34. Asia Pacific Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 35. Asia Pacific Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 36. Asia Pacific Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 37. China Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 38. China Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 39. China Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 40. China Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 41. Japan Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 42. Japan Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 43. Japan Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 44. Japan Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 45. India Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 46. India Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 47. India Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 48. India Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 49. South Korea Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 50. South Korea Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 51. South Korea Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 52. South Korea Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 53. Taiwan Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 54. Taiwan Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 55. Taiwan Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 56. Taiwan Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 57. Australia Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 58. Australia Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 59. Australia Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 60. Australia Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 61. Rest of Asia-Pacific Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 62. Rest of Asia-Pacific Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 63. Rest of Asia-Pacific Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 65. Europe Dysmenorrhea Treatment, by Country USD Million (2017-2022)
  • Table 66. Europe Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 67. Europe Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 68. Europe Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 69. Europe Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 70. Germany Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 71. Germany Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 72. Germany Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 73. Germany Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 74. France Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 75. France Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 76. France Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 77. France Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 78. Italy Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 79. Italy Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 80. Italy Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 81. Italy Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 82. United Kingdom Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 83. United Kingdom Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 84. United Kingdom Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 85. United Kingdom Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 86. Netherlands Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 87. Netherlands Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 88. Netherlands Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 89. Netherlands Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 90. Rest of Europe Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 91. Rest of Europe Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 92. Rest of Europe Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 93. Rest of Europe Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 94. MEA Dysmenorrhea Treatment, by Country USD Million (2017-2022)
  • Table 95. MEA Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 96. MEA Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 97. MEA Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 98. MEA Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 99. Middle East Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 100. Middle East Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 101. Middle East Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 102. Middle East Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 103. Africa Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 104. Africa Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 105. Africa Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 106. Africa Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 107. North America Dysmenorrhea Treatment, by Country USD Million (2017-2022)
  • Table 108. North America Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 109. North America Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 110. North America Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 111. North America Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 112. United States Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 113. United States Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 114. United States Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 115. United States Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 116. Canada Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 117. Canada Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 118. Canada Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 119. Canada Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 120. Mexico Dysmenorrhea Treatment, by Application USD Million (2017-2022)
  • Table 121. Mexico Dysmenorrhea Treatment, by Treatment USD Million (2017-2022)
  • Table 122. Mexico Dysmenorrhea Treatment, by Drug Used USD Million (2017-2022)
  • Table 123. Mexico Dysmenorrhea Treatment, by End-Use USD Million (2017-2022)
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Dysmenorrhea Treatment: by Application(USD Million)
  • Table 144. Dysmenorrhea Treatment Primary Dysmenorrhea , by Region USD Million (2023-2028)
  • Table 145. Dysmenorrhea Treatment Secondary Dysmenorrhea , by Region USD Million (2023-2028)
  • Table 146. Dysmenorrhea Treatment: by Treatment(USD Million)
  • Table 147. Dysmenorrhea Treatment Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) , by Region USD Million (2023-2028)
  • Table 148. Dysmenorrhea Treatment Hormonal Therapy , by Region USD Million (2023-2028)
  • Table 149. Dysmenorrhea Treatment: by Drug Used(USD Million)
  • Table 150. Dysmenorrhea Treatment Ibuprofen , by Region USD Million (2023-2028)
  • Table 151. Dysmenorrhea Treatment Ketoprofen , by Region USD Million (2023-2028)
  • Table 152. Dysmenorrhea Treatment Naproxen , by Region USD Million (2023-2028)
  • Table 153. Dysmenorrhea Treatment: by End-Use(USD Million)
  • Table 154. Dysmenorrhea Treatment Hospitals , by Region USD Million (2023-2028)
  • Table 155. Dysmenorrhea Treatment Ambulatory Centres , by Region USD Million (2023-2028)
  • Table 156. Dysmenorrhea Treatment Specialty Clinics , by Region USD Million (2023-2028)
  • Table 157. South America Dysmenorrhea Treatment, by Country USD Million (2023-2028)
  • Table 158. South America Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 159. South America Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 160. South America Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 161. South America Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 162. Brazil Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 163. Brazil Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 164. Brazil Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 165. Brazil Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 166. Argentina Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 167. Argentina Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 168. Argentina Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 169. Argentina Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 170. Rest of South America Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 171. Rest of South America Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 172. Rest of South America Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 173. Rest of South America Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 174. Asia Pacific Dysmenorrhea Treatment, by Country USD Million (2023-2028)
  • Table 175. Asia Pacific Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 176. Asia Pacific Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 177. Asia Pacific Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 178. Asia Pacific Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 179. China Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 180. China Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 181. China Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 182. China Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 183. Japan Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 184. Japan Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 185. Japan Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 186. Japan Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 187. India Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 188. India Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 189. India Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 190. India Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 191. South Korea Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 192. South Korea Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 193. South Korea Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 194. South Korea Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 195. Taiwan Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 196. Taiwan Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 197. Taiwan Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 198. Taiwan Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 199. Australia Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 200. Australia Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 201. Australia Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 202. Australia Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 203. Rest of Asia-Pacific Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 204. Rest of Asia-Pacific Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 205. Rest of Asia-Pacific Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 206. Rest of Asia-Pacific Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 207. Europe Dysmenorrhea Treatment, by Country USD Million (2023-2028)
  • Table 208. Europe Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 209. Europe Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 210. Europe Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 211. Europe Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 212. Germany Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 213. Germany Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 214. Germany Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 215. Germany Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 216. France Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 217. France Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 218. France Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 219. France Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 220. Italy Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 221. Italy Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 222. Italy Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 223. Italy Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 224. United Kingdom Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 225. United Kingdom Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 226. United Kingdom Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 227. United Kingdom Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 228. Netherlands Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 229. Netherlands Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 230. Netherlands Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 231. Netherlands Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 232. Rest of Europe Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 233. Rest of Europe Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 234. Rest of Europe Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 235. Rest of Europe Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 236. MEA Dysmenorrhea Treatment, by Country USD Million (2023-2028)
  • Table 237. MEA Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 238. MEA Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 239. MEA Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 240. MEA Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 241. Middle East Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 242. Middle East Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 243. Middle East Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 244. Middle East Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 245. Africa Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 246. Africa Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 247. Africa Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 248. Africa Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 249. North America Dysmenorrhea Treatment, by Country USD Million (2023-2028)
  • Table 250. North America Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 251. North America Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 252. North America Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 253. North America Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 254. United States Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 255. United States Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 256. United States Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 257. United States Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 258. Canada Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 259. Canada Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 260. Canada Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 261. Canada Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 262. Mexico Dysmenorrhea Treatment, by Application USD Million (2023-2028)
  • Table 263. Mexico Dysmenorrhea Treatment, by Treatment USD Million (2023-2028)
  • Table 264. Mexico Dysmenorrhea Treatment, by Drug Used USD Million (2023-2028)
  • Table 265. Mexico Dysmenorrhea Treatment, by End-Use USD Million (2023-2028)
  • Table 266. Research Programs/Design for This Report
  • Table 267. Key Data Information from Secondary Sources
  • Table 268. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dysmenorrhea Treatment: by Application USD Million (2017-2022)
  • Figure 5. Global Dysmenorrhea Treatment: by Treatment USD Million (2017-2022)
  • Figure 6. Global Dysmenorrhea Treatment: by Drug Used USD Million (2017-2022)
  • Figure 7. Global Dysmenorrhea Treatment: by End-Use USD Million (2017-2022)
  • Figure 8. South America Dysmenorrhea Treatment Share (%), by Country
  • Figure 9. Asia Pacific Dysmenorrhea Treatment Share (%), by Country
  • Figure 10. Europe Dysmenorrhea Treatment Share (%), by Country
  • Figure 11. MEA Dysmenorrhea Treatment Share (%), by Country
  • Figure 12. North America Dysmenorrhea Treatment Share (%), by Country
  • Figure 13. Global Dysmenorrhea Treatment share by Players 2022 (%)
  • Figure 14. Global Dysmenorrhea Treatment share by Players (Top 3) 2022(%)
  • Figure 15. Global Dysmenorrhea Treatment share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 19. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2022
  • Figure 21. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 23. Teva Pharmaceuticals USA, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Teva Pharmaceuticals USA, Inc. (United States) Revenue: by Geography 2022
  • Figure 25. Color Seven Co., Ltd. (South Korea) Revenue, Net Income and Gross profit
  • Figure 26. Color Seven Co., Ltd. (South Korea) Revenue: by Geography 2022
  • Figure 27. Beurer GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Beurer GmbH (Germany) Revenue: by Geography 2022
  • Figure 29. Mylan N. V. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Mylan N. V. (United States) Revenue: by Geography 2022
  • Figure 31. Boehringer Ingelheim International GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Boehringer Ingelheim International GmbH (Germany) Revenue: by Geography 2022
  • Figure 33. PMS4PMS, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 34. PMS4PMS, LLC (United States) Revenue: by Geography 2022
  • Figure 35. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 36. Sanofi (France) Revenue: by Geography 2022
  • Figure 37. Nobelpharma Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 38. Nobelpharma Co., Ltd. (Japan) Revenue: by Geography 2022
  • Figure 39. ObsEva (Switzerland) Revenue, Net Income and Gross profit
  • Figure 40. ObsEva (Switzerland) Revenue: by Geography 2022
  • Figure 41. Myovant Sciences Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 42. Myovant Sciences Ltd. (United Kingdom) Revenue: by Geography 2022
  • Figure 43. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. AbbVie Inc. (United States) Revenue: by Geography 2022
  • Figure 45. Alvogen (United States) Revenue, Net Income and Gross profit
  • Figure 46. Alvogen (United States) Revenue: by Geography 2022
  • Figure 47. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 48. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2022
  • Figure 49. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 50. Sanofi (France) Revenue: by Geography 2022
  • Figure 51. Lupin Pharmaceuticals, Inc. (India) Revenue, Net Income and Gross profit
  • Figure 52. Lupin Pharmaceuticals, Inc. (India) Revenue: by Geography 2022
  • Figure 53. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 54. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2022
  • Figure 55. Global Dysmenorrhea Treatment: by Application USD Million (2023-2028)
  • Figure 56. Global Dysmenorrhea Treatment: by Treatment USD Million (2023-2028)
  • Figure 57. Global Dysmenorrhea Treatment: by Drug Used USD Million (2023-2028)
  • Figure 58. Global Dysmenorrhea Treatment: by End-Use USD Million (2023-2028)
  • Figure 59. South America Dysmenorrhea Treatment Share (%), by Country
  • Figure 60. Asia Pacific Dysmenorrhea Treatment Share (%), by Country
  • Figure 61. Europe Dysmenorrhea Treatment Share (%), by Country
  • Figure 62. MEA Dysmenorrhea Treatment Share (%), by Country
  • Figure 63. North America Dysmenorrhea Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bayer AG (Germany)
  • GlaxoSmithKline plc (United Kingdom)
  • Pfizer Inc. (United States)
  • Teva Pharmaceuticals USA, Inc. (United States)
  • Color Seven Co., Ltd. (South Korea)
  • Beurer GmbH (Germany)
  • Mylan N. V. (United States)
  • Boehringer Ingelheim International GmbH (Germany)
  • PMS4PMS, LLC (United States)
  • Sanofi (France)
  • Nobelpharma Co., Ltd. (Japan)
  • ObsEva (Switzerland)
  • Myovant Sciences Ltd. (United Kingdom)
  • AbbVie Inc. (United States)
  • Alvogen (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Sanofi (France)
  • Lupin Pharmaceuticals, Inc. (India)
  • Sun Pharmaceutical Industries Ltd. (India)
Select User Access Type

Key Highlights of Report


Mar 2023 241 Pages 62 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Dysmenorrhea Treatment Market Quantitative research analysis
Global Dysmenorrhea Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Dysmenorrhea Treatment market are Bayer AG (Germany), GlaxoSmithKline plc (United Kingdom), Pfizer Inc. (United States), Teva Pharmaceuticals USA, Inc. (United States), Color Seven Co., Ltd. (South Korea), Beurer GmbH (Germany), Mylan N. V. (United States), Boehringer Ingelheim International GmbH (Germany), PMS4PMS, LLC (United States), Sanofi (France), Nobelpharma Co., Ltd. (Japan), ObsEva (Switzerland), Myovant Sciences Ltd. (United Kingdom), AbbVie Inc. (United States), Alvogen (United States), F. Hoffmann-La Roche Ltd (Switzerland), Sanofi (France), Lupin Pharmaceuticals, Inc. (India) and Sun Pharmaceutical Industries Ltd. (India), to name a few.
is dominating the Dysmenorrhea Treatment Market.
"" is seen as one of the major challenges by many Industry Players of Dysmenorrhea Treatment Market
The Dysmenorrhea Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Dysmenorrhea Treatment market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Dysmenorrhea Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Silk Protein Comprehensive Study by Type (Fibroin, Sericin), Nature (Recyclable, Biodegradable, Biocompatible, Others), Industry Verticals (Cosmetics, Personal Care, Medical, Others), Sales Channel (...
$ 3500
Alectinib Drugs Comprehensive Study by Application (Hospitals, Clinics, Others), Capacity (1 Capsule, 140 Capsules, 28 Capsules, 26 Capsules), End Use (Unresectable NSCLC, Advanced NSCLC, Recurrent N...
$ 3500
Protein Stability Analysis Comprehensive Study by Type (Reagents and Assay Kits, Instruments, Consumable and Accessories, Software), Technique (Chromatography, Spectroscopy, Surface Plasma Resonance ...
$ 3750
Aerosols Budesonide Comprehensive Study by Application (Hospitals, Specialty Clinics, Over-the-Counter (OTC)), Distribution Channel (Online (E-Commerce Websites, Third Party Websites), Offline (Retai...
$ 3750
Oral Osmotic Laxative Comprehensive Study by Drug (Sodium sulfate, Magnesium carbonate, Magnesium citrate, Lactitol, Mannitol), Form (Powder, Injectable, Syrup, Others), End Use (Over-the-Counter (OT...
$ 3450
Urokinase Lyophilized Powder Comprehensive Study by Type (Less than 10000IU, 10000-100000IU, 100000-1000000IU, More than 1000000IU), Application (Eye Care, Cholesterol Embolization, Allergy Resistanc...
$ 3650